25984-63-8NC(=S)c1ccc(O)cc1VDTNKXSVUGXUOJ-UHFFFAOYSA-N25984-63-8DTXSID40420703CHEMBL2441358Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (14.6%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 48 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Beschreibung4-Hydroxythiobenzamide is a key intermediate in febuxostat, a highly effective drug for treating gout. In addition, 4-hydroxythiobenzamide has been used to synthesize a variety of bioactive compounds, such as PPARγ agonists (used to increase high-density lipoprotein cholesterol levels) and potent CDK5 inhibitors (used in neurological disorders and cancer research).
Verwenden4-Hydroxythiobenzamide is used in the synthesis of PPARα agonists used in increasing HDLc levels. Also used in the synthesis of potent CDK5 inhibitors in the treatment of Alzheimer’s disease.